Royal Bank of Canada
CNTA

Royal Bank of Canada’s Centessa Pharmaceuticals CNTA Stock Holding History

Royal Bank of Canada’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46K Sell
1,164
-4,408
-79% -$113K ﹤0.01% 5535
2025
Q4 		$139K Buy
5,572
+168
+3% +$4.25K ﹤0.01% 5008
2025
Q3 		$131K Sell
5,404
-2,094
-28% -$37.2K ﹤0.01% 5347
2025
Q2 		$98K Buy
7,498
+743
+11% +$9.41K ﹤0.01% 5617
2025
Q1 		$97K Sell
6,755
-1,588
-19% -$26K ﹤0.01% 5241
2024
Q4 		$139K Buy
8,343
+2,064
+33% +$34.2K ﹤0.01% 5109
2024
Q3 		$101K Buy
6,279
+5,162
+462% +$63.2K ﹤0.01% 5335
2024
Q2 		$10K Buy
1,117
+501
+81% +$4.75K ﹤0.01% 6327
2024
Q1 		$7K Buy
616
+525
+577% +$4.97K ﹤0.01% 6316
2023
Q4 		$1K Buy
91
+71
+355% +$476 ﹤0.01% 6901
2023
Q3 		$0 Sell
20
-165
-89% -$1.13K ﹤0.01% 7138
2023
Q2 		$1K Buy
185
+115
+164% +$546 ﹤0.01% 6977
2023
Q1 		$0 Sell
70
-55
-44% -$201 ﹤0.01% 7117
2022
Q4 		$0 Buy
+125
New +$463 ﹤0.01% 7281
2021
Q4 		– Sell
-453
Closed -$8K – 7672
2021
Q3 		$8K Buy
+453
New +$9.38K ﹤0.01% 7027

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Royal Bank of Canada's CNTA Position: Q1 2026 in Review

Royal Bank of Canada reduced its Centessa Pharmaceuticals (CNTA) stake by 79% in Q1 2026, selling an estimated $113K and leaving 1,164 shares worth $46K. The position accounts for ﹤0.01% of the portfolio, ranked #5535.

Royal Bank of Canada first reported a position in CNTA in Q3 2021 and has held it in 15 quarters since. The position peaked at $139K in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Royal Bank of Canada held 1,164 shares of Centessa Pharmaceuticals worth $46K as of Q1 2026.
  • Royal Bank of Canada sold 4,408 Centessa Pharmaceuticals shares in Q1 2026, an estimated $113K.
  • Centessa Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5535 holding.
  • Royal Bank of Canada first reported a position in Centessa Pharmaceuticals in Q3 2021 and has held it in 15 quarters since.
  • Royal Bank of Canada's Centessa Pharmaceuticals position peaked at $139K in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.